Current Report Filing (8-k)
March 28 2023 - 4:40PM
Edgar (US Regulatory)
0001551152
false
Common Stock, $0.01 Par Value
ABBV
0001551152
2023-03-28
2023-03-28
0001551152
us-gaap:CommonStockMember
exch:XNYS
2023-03-28
2023-03-28
0001551152
exch:XCHI
us-gaap:CommonStockMember
2023-03-28
2023-03-28
0001551152
abbv:SeniorNotes1.500Percentdue2023Member
exch:XNYS
2023-03-28
2023-03-28
0001551152
abbv:SeniorNotes1.375Percentdue2024Member
exch:XNYS
2023-03-28
2023-03-28
0001551152
abbv:SeniorNotes1.250Percentdue2024Member
exch:XNYS
2023-03-28
2023-03-28
0001551152
abbv:SeniorNotes0.750Percentdue2027Member
exch:XNYS
2023-03-28
2023-03-28
0001551152
abbv:SeniorNotes2.125Percentdue2028Member
exch:XNYS
2023-03-28
2023-03-28
0001551152
abbv:SeniorNotes2.625Percentdue2028Member
exch:XNYS
2023-03-28
2023-03-28
0001551152
abbv:SeniorNotes2.125Percentdue2029Member
exch:XNYS
2023-03-28
2023-03-28
0001551152
abbv:SeniorNotes1.250Percentdue2031Member
exch:XNYS
2023-03-28
2023-03-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 28, 2023
ABBVIE INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35565 |
|
32-0375147 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.01 Par Value |
|
ABBV |
|
New York Stock Exchange Chicago Stock Exchange |
1.500% Senior Notes due 2023 |
|
ABBV23B |
|
New York Stock Exchange |
1.375% Senior Notes due 2024 |
|
ABBV24 |
|
New York Stock Exchange |
1.250% Senior Notes due 2024 |
|
ABBV24B |
|
New York Stock Exchange |
0.750% Senior Notes due 2027 |
|
ABBV27 |
|
New York Stock Exchange |
2.125% Senior Notes due 2028 |
|
ABBV28 |
|
New York Stock Exchange |
2.625% Senior Notes due 2028 |
|
ABBV28B |
|
New York Stock Exchange |
2.125% Senior Notes due 2029 |
|
ABBV29 |
|
New York Stock Exchange |
1.250% Senior Notes due 2031 |
|
ABBV31 |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Common Stock, $0.01 Par Value |
ABBV |
Item 1.01 |
Entry into a Material Definitive Agreement |
Second Amended and Restated Revolving Credit Agreement
On March 28, 2023 (the “Effective Date”), AbbVie
Inc. (“AbbVie”) entered into an amended and restated revolving credit agreement (the “Second Amended and Restated Revolving
Credit Agreement”) among AbbVie, as borrower, the lenders and other parties party thereto and JPMorgan Chase Bank, N.A., as administrative
agent (in such capacity, the “Agent”), providing for the amendment and restatement, effective as of the Effective Date, of
that certain amended and restated revolving credit agreement, dated as of August 27, 2019, among AbbVie, as borrower, the lenders
and other parties party thereto and the Agent. The Second Amended and Restated Revolving Credit Agreement: (i) increases the unsecured
revolving credit facility commitments from $4.0 billion to $5.0 billion and (ii) extends the maturity date of the facility from August 27,
2024 to March 28, 2028. The foregoing summary of the Second Amended and Restated Revolving Credit Agreement does not purport to be
complete and is subject to, and qualified in its entirety by, the full text of the Second Amended and Restated Revolving Credit Agreement,
which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 2.03 |
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant |
On March 28, 2023, AbbVie entered into the Second Amended and
Restated Revolving Credit Agreement as described in Item 1.01 above. The description of the Second Amended and Restated Revolving Credit
Agreement set forth in Item 1.01 above is hereby incorporated by reference.
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ABBVIE INC. |
|
|
|
|
By: |
/s/ Scott T. Reents |
Date: March 28, 2023 |
Name: |
Scott T. Reents |
|
Title: |
Executive Vice President, Chief Financial Officer |
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024